HCW Biologics Q1 net loss widens to $7.5M; going concern doubt persists

HCW Biologics Inc.

2024-Q1 EPS reported -$0.20 revenue$1,126,712

Net loss of $7.5M vs $5.1M in Q1 2023; revenue rose to $1.1M from $41,883 due to Wugen sales.
G&A expenses surged 94% to $6.0M driven by legal costs for Altor/NantCell arbitration hearing set for May 20.
Completed Phase 1/1b trials for HCW9218 in solid tumors; RP2D established; plans ovarian cancer Phase 2 with UPMC in H2 2024.
Raised $6.1M YTD; bridge financing target $10M in secured notes ($3.6M issued); going concern uncertainty remains.
IND for HCW9302 in autoimmune disease planned for Q3 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

HCW Biologics Inc. reported first quarter ended March 31, 2024 results: revenue $1.1 million, net income $7.5 million.

Period: first quarter ended March 31, 2024
Revenue: $1.1 million
Net income: $7.5 million
Result: reported results

Exact text from the filing

we plan to submit in the third quarter of 2024. 2 First Quarter 2024 Financial Results • Revenues: Revenues for the first quarters ended March 31, 2023 and 2024 were $41,883 and $1.1 million, respectively. Revenues in both periods were derived exclusively from the sale of licensed molecules to the Company’s licensee, Wugen. The licensed molecules are one of the

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

HCW Biologics Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-060553

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.